Scinai Immunotherapeutics (SCNI) Cash & Current Investments (2015 - 2026)

Scinai Immunotherapeutics (SCNI) has 12 years of Cash & Current Investments data on file, last reported at $3.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 270918.28% year-over-year to $3.1 billion; the trailing twelve-month figure through Mar 2026 stood at $3.1 billion (up 270918.28% YoY), and the FY2025 full-year result was $151.7 million, up 7139.19% from the prior year.
• Cash & Current Investments climbed to $3.1 billion in Q1 2026, from $151.7 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $3.1 billion in Q1 2026 to a low of $1.1 million in Q1 2025.
• A 5-year average of $211.4 million and a median of $10.1 million in 2022 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments tumbled 77.69% in 2025 and soared 270918.28% in 2026, its largest moves.
• Tracing SCNI's Cash & Current Investments over 5 years: stood at $14.2 million in 2022, then tumbled by 64.76% to $5.0 million in 2023, then slumped by 58.18% to $2.1 million in 2024, then surged by 7139.19% to $151.7 million in 2025, then jumped by 1953.26% to $3.1 billion in 2026.
• Business Quant data shows SCNI's Cash & Current Investments at $3.1 billion in Q1 2026, $151.7 million in Q4 2025, and $1.3 million in Q2 2025.